Sanofi-Aventis Korea launches sustained-release form of sodium valproate

Published: 2006-11-20 06:56:00

Updated: 2006-11-20 06:56:00

Depakine Chronosphere (sodium vaproate), a new sustained-release sachet formulation for the treatment of epilepsy, has been launched from November 1, according to Sanofi-Aventis Korea.

Valproic acid is an oral anticonvulsant that is chemically unrelated to other anticonvulsants. Valproate sodi...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK